Kornimate/medical-research-clean huggingface dataset:
web-based family outreach program for cancer prevention in high-risk families

Conditions: Malignant Neoplasm

Summary: this trial develops a patient-driven self-navigated web-based family outreach program for cancer prevention in high-risk families. creating the family outreach program may help to improve the way in which genetic test results are communicated within families and increase the number of at-risk relatives who become aware of their risks.

primary objectives: i. to develop a secure, web-based program for family outreach in clinical cancer genetics (ccg). ii. the long-term goals of this program are expected to include, but are not limited to the following: iia. to enable families with inherited cancer susceptibility and/or at increased familial risk of cancer to provide personal and family history of neoplasia through a convenient and self-directed program. iib. to enable communication of possible inherited cancer susceptibility with and among family members through the web-based portal. iic. to facilitate genetic testing, screening and prevention strategies in those at risk. iid. establish high-risk cohort for optional participation in research and clinical trials. outline: patients communicate with at-risk family members to share genetic test results and other relevant information, as well as to learn more about their disease via family outreach program website. at risk family members are then contacted by a study coordinator or genetic counselor for further follow-up. at-risk relatives receive resources to facilitate understanding of their at-risk status and to facilitate predictive testing.

Eligibility criteria:
inclusion criteria: * individuals who have been diagnosed with a hereditary cancer-causing mutation. individuals may be identified through clinical testing as patients at md anderson or patients whose mutation was identified at an outside institution who contact the registry * individuals that have clinical suspicion for syndromic cancer susceptibility, but in whom mutational testing has been nondiagnostic (depending on condition in question, nondiagnostic testing may be as little as 10%, as in familial adenomatous polyposis \[fap\], or as high as 70% in suspected hereditary diffuse gastric cancer or hdgc) * at-risk family members of individuals with a cancer causing mutation or of individuals with nondiagnostic testing notwithstanding presence of likely syndromic cancer. such patients will in most cases not be md anderson patients. note: the enrollment, consenting, and evaluation process anticipates and addresses this. exclusion criteria: * index patients who test negative for a cancer causing mutation, except for those agreeing to provide family history (fh) that is informative for at-risk individuals when no other source of such information is available * patients who are unwilling or are unable to provide informed consent
a study to evaluate the safety and efficacy of afamelanotide in patients with xeroderma pigmentosum (xp)

Conditions: Xeroderma Pigmentosum

Summary: the cuv156 study will evaluate the safety of afamelanotide in xp-c patients, as well as the drug's ability to assist reparative processes following ultraviolet (uv) provoked dna damage of the skin. it will assess whether scenesse® increases the amount of uv light needed to cause dna damage of skin cells, as well as the extent of skin repair before and after treatment.


Eligibility criteria:
inclusion criteria: * male or female patient with a molecular-genetically confirmed diagnosis of xp-c; * aged 18-75 years. exclusion criteria: * known allergy to afamelanotide or the polymer contained in the implant; * presence of severe hepatic disease or hepatic impairment; * renal impairment; * any other medical condition which may interfere with the study protocol; * female who is pregnant (confirmed by positive urine beta-human chorionic gonadotropin pregnancy test) or lactating; * females of child-bearing potential (pre-menopausal, not surgically sterile) not using highly effective contraceptive measures with a failure rate of less than 1% per year when used consistently and correctly (i.e. oral contraceptives, intrauterine device) or a life-style excluding pregnancy, for up to three months after the last implant administration; * sexually active man with a partner of child-bearing potential (pre-menopausal, not surgically sterile) who is not using highly effective contraceptive measures, as described above; * use of any other prior and concomitant therapy which may interfere with the objective of the study, within 30 days prior to the screening visit; * participation in a clinical trial for an investigational agent within 30 days prior to the screening visit.
effect of laughter therapy on hemodıalysıs patıents

Conditions: Laughter Therapy; Depression, Anxiety; Hemodialysis; Life Quality

Summary: internet-based behavioral therapy applications made during the quarantine and isolation period during the pandemic process, and the application of laughter therapy, which is a group-oriented technique that increases the feeling of togetherness and happiness, can be used as an online method to reach large masses. however, since there are a limited number of studies in the literature on online laughter therapy in patients and not all sessions are online in the study, it was thought that more and methodological studies are needed to confirm the effectiveness of the therapy on the applicability of the online platform. therefore, this study was conducted to evaluate the blood cortisol levels, depression, anxiety, stress levels and quality of life of laughter therapy in hemodialysis patients.

in this research, laughter therapy applied to hemodialysis patients; this is an experimental design with pretest and posttest control groups in order to examine the effects on serum cortisol levels, depression, anxiety, stress levels and quality of life. the study will be conducted between march 2023 and june 2023 on 80 patients who are receiving hemodialysis treatment in two dialysis centers in zonguldak city center and meet the inclusion criteria. introductory information form, depression anxiety and stress scale, kidney disease quality of life form will be used in the study and blood samples will be taken from the patients for cortisol. laughter therapy will be applied three days a week, for a total of 12 sessions for 4 weeks.

Eligibility criteria:
inclusion criteria: * do not prevent you from doing laughter yoga (having undergone abdominal surgery in the last three months, uncontrollable hypertension, chronic cough, incontinence, acute low back pain, acute mental disorders, consumption of antipsychotic drugs, glaucoma, hernia, epilepsy) * history of psychiatric illness (major depression, alcohol abuse, substance abuse, schizophrenia or paranoid disorders, personality disorder, somatoform disorder) * standardized mini mental test (smmt) score 24\> * not doing laughter yoga before * being able to use smart phone/computer/tablet and using internet applications actively exclusion criteria: * initiation of medication that may affect serum cortisol levels * diagnosis of psychiatric illness during sessions * surgery on the abdominal region during laughter sessions
muscle weakness and post-traumatic knee oa

Conditions: Meniscectomy

Summary: this is a single-center, randomized, single-blind (evaluator) study. enrolled patients had a traumatic meniscal tear and underwent meniscectomy. the study included 6 weeks (12 visits) of standard or quadriceps intensive rehabilitation. the objective of the study was to determine the effect of quadriceps intensive rehabilitation on knee function and articular cartilage.


Eligibility criteria:
inclusion criteria: 1. traumatic onset meniscal tear (i.e. specific mechanism of injury) 2. meniscectomy surgery performed within 12 months of index injury 3. meniscal tear confirmed at the time of surgery 4. subject anticipates living in close proximity to gainesville for one year following surgery. exclusion criteria: 1. bilateral injury 2. concomitant ligamentous injury 3. previous knee injury 4. articular cartilage defect \> grade ii on outerbridge scale 5. patellofemoral joint pain \> 3/10 with activity 6. lower limb alignment \> 5 degrees of valgus or varus 7. contraindication to an mr examination including: a pacemaker, metal implants which are not mr compatible, pregnancy and severe claustrophobia.

Keywords: quadriceps strength knee rehabilitation
evaluation of maternal mental health following ultrasonography detection of fetal congenital anomalies

Conditions: Mental Disorder

Summary: the purpose of this study is to evaluate maternal mental health during antenatal and postnatal periods after ultrasonography diagnosis of fetal anomalies.

fetal congenital anomalies are responsible for a great deal of abortions in desired pregnancies . in clinical practice, prenatal screening programs in 1st and 2nd trimester target both chromosomal and structural abnormalities. these congenital anomalies are classified as minor and major anomalies than may lead to death or stillbirth . half of all anomalies are detectable during weeks 18-22 of pregnancy. due to the advances occurring in ultrasonography and screening paradigms, the rate of diagnosed anomalies is increasing dramatically which in turn leading to psychological distress in the pregnant mother. receiving a diagnosis of fetal anomaly is a highly stressful and potentially traumatic event that can elicit immediate feelings of grief, loss, anger, depression, and anxiety. however, the foreknowledge of a fetal anomaly during pregnancy may enable the mother to prepare mentally resulting in reduced maternal stress after delivery. the american college of medical genetics recommends underscoring the importance of psychological assessment and substantive communication with parents facing a prenatal diagnosis of fetal anomaly. despite the accessibility of establishing the significant symptoms of maternal psychological distress, the evidence on the definite nature of this distress in consideration to other life stressors and an accurate the prediction of women vulnerability in the critical period have not been clear yet due to many methodological issues. identification of women at highest risk for poor adaptation to the diagnosis may allow for targeted psychological support services for those most vulnerable.

Eligibility criteria:
inclusion criteria: * pregnant women with confirmed pregnancy with viable fetus (whether singleton or multiple) * fetal anomaly should be diagnosed with ultrasonography (whether minor or major) after 12 weeks of gestational age exclusion criteria: - women with history of psychiatric disorders.
increased expression of adiponectin receptor 2 in the mononuclear cells in children with prader-willi syndrome

Conditions: Obesity; Prader-Willi Syndrome

Summary: the inflammatory process is involved in the pathogenesis of obesity. prader-willi syndrome (pws) is a genetic model of syndromic obesity. adiponectin is an adipokine with potent anti-inflammatory properties, and its effect is mediated through adiponectin receptors 1 (adipor1) and 2 (adipor2). objective of this study is to compare the expression of adipor1, adipor2, and adiponectin in peripheral blood mononuclear cells (pbmcs) in pws children and obese control and to correlate receptor expression with insulin sensitivity and obesity-related parameters.


Eligibility criteria:
inclusion criteria: * children with prader-willi syndrome * children with simple obesity exclusion criteria: * subjects with diabetes mellitus (fasting plasma glucose \> 126 mg/dl with a 2-h oral glucose tolerance test value of \>200 mg/dl)

Keywords: adiponectin adiponectin receptor prader-willi syndrome
topical finasteride in the treatment of idiopathic hirsutism

Conditions: Idiopathic Hirsutism

Summary: the purpose of this study is to evaluate the efficacy of topical finasteride in the treatment of idiopathic hirsutism


Eligibility criteria:
inclusion criteria: * idiopathic hirsutism which is defined as normal levels of androgens and normal ovulation * normal serum prolactin exclusion criteria: * pregnancy * simultaneous use of other drugs for the treatment of hirsutism
review of multimodality management of anaplastic thyroid cancer

Conditions: Anaplastic Thyroid Cancer

Summary: to describe the outcome of patients with anaplastic thyroid cancer treated with hyperfractionated radiotherapy and concomitant chemotherapy


Eligibility criteria:
inclusion criteria: * anaplastic thyroid cancer treated with multimodality treatment exclusion criteria: * differentiated thyroid cancer

Keywords: anaplastic thyroid cancer chemotherapy radiotherapy
heart rate variability and its association with symptom of orthostatic hypotension in spinal cord injury

Conditions: Spinal Cord Injuries; Orthostatic Hypotension; Heart Rate Variability

Summary: in this study, the sci patients were sub-grouped on the basis of symptoms into symptomatic and asymptomatic groups and measured hrv during resting and tilt up tests to compare their cardiovascular autonomic functions.

in study protocol and the subjects were asked to lie down quietly for 5 minutes, closing their eyes and avoiding talking, moving hand, legs and body, and coughing during the test. r-r interval and blood pressure were measured beat-to-beat using finometer® pro (finapres medical systems, amsterdam, netherlands) for 6 minutes each in two positions, supine and 60-degree angle on the tilt table.

Eligibility criteria:
inclusion criteria: * spinal cord injury with or without oh * aged 19 or older * asia impairment scale (ais) a to d * neurological level of injury above t6. exclusion criteria: * those with heart and respiratory diseases, neurological diseases other than sci - medically unstable states * those who are taking medications affecting bp that cannot be stopped

Keywords: spinal cord injuries orthostatic hypotension heart rate variability autonomic nervous system
variation in success of intravenous (iv) placement with observation using new techniques

Conditions: Catheterization; Peripheral Phlebotomy

Summary: children fear having an intravenous (iv) needle placed because of the pain that they will experience. the more needle punctures that a child has to endure before the iv is successfully placed, the greater the pain experienced and anxiety suffered. in addition, false starts increase the demands on medical staff and can increase the length of the emergency department stay. often, veins are difficult to see or feel, particularly in an unwell, dehydrated child or in young infants who have more fat below the skin surface. also, the venous pattern below the skin surface naturally varies from person to person and therefore success in placing ivs leaves room for improvement. technology may be able to play an important role is improving the rates of success. the investigators wish to investigate whether the use of either an ultrasound machine or a veinviewer machine can improve the rate of success of the initial attempt (skin puncture) at peripheral iv placement in comparison to the current standard approach.

peripheral iv line placement is one of the most common and challenging painful procedures performed in the pediatric emergency department (ped). the lack of a clear visual guide for iv placement often leads to multiple painful attempts; delays in urgent treatment; increased use of human resources; increased costs; and increased anxiety in the patient, the parents and the staff. the research plan is a randomized controlled trial (rct) to compare the use of two new technologies with the current standard method for vein location and iv placement in children.we would like to know if either of these technologies improve rates of successful iv placement on first attempt. furthermore we would like to know if either technology leads to decreased time spent by staff on the procedure or decreased overall number of painful attempts. information on nursing satisfaction, parental satisfaction and cost analysis will also be obtained.

Eligibility criteria:
inclusion criteria: * children 0-16 presenting to the pediatric emergency department (ped) * require iv as part of routine care * knowledge of english language exclusion criteria: * child in critical condition * child requires urgent iv placement * central line available

Keywords: venipuncture randomized controlled trial intravenous access children pediatric emergency department peripheral intravenous catheterization catheterization, peripheral phlebotomy
a study of the effect of enantone lp 11.25 mg (leuprorelin) on the histological progression of indolent prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to assess two treatment strategies (leuprorelin treatment and active surveillance without androgen deprivation) for indolent prostate cancer and to compare their therapeutic benefit for management of patients with low-risk, localized prostate cancer.

the drug being tested in this study is called leuprorelin. leuprorelin is being tested to treat people who have prostate cancer. study assessments will include adverse events, prostatic-specific antigen (psa) levels, and prostate biopsies. the study will enroll approximately 120 patients. participants will be randomly assigned (by chance, like flipping a coin) to a treatment group that will receive leuprorelin 11.25 mg (as one injection) or to an untreated observation group. patients in the leuprorelin group will also receive bicalutamide 50 mg, a non-steroidal antiandrogen, once daily for 15 days to prevent a flare-up. this multi-center trial will be conducted in france. the overall time to participate in this study is 12 months. after the screening visit, participants will make 6 visits to the clinic.

Eligibility criteria:
inclusion criteria: 1. is an out-patient 50 to 80 years old. 2. has read, understood, signed and dated the informed consent. 3. has indolent prostate cancer defined by: * clinical stage t1c or t2a. * biopsy cores of which at least 12 reveal the presence of positive cores and the absence of cores with tumor length \> 3 mm. * absence of grade 4 cells (gleason \<7). * prostate specific antigen (psa) levels \<10 ng/ml. 4. has a life expectancy \> 5 years. 5. has accepted the principle of active surveillance. 6. is willing to participate in the study for a minimum of fifteen months. exclusion criteria: 1. has prior androgen deprivation including a 5-alpha reductase inhibitor (finasteride or dutasteride) within the last 6 months. 2. has psychological failure related to prostate cancer therapy. 3. has any active disorder likely to affect the conduct of the study or the patient's prognosis during the study. 4. has a mental deficiency or any other reason that may hinder the understanding or strict application of the protocol. 5. is under judicial protection, tutorship or curatorship. 6. is unlikely to attend control visits. 7. is currently enrolled in an investigational study or has participated in another investigational study within the last 3 months. 8. has an allergy or hypersensitivity to any components of leuprorelin (enantone lp) 11.25 mg or casodex® 50 mg. 9. has a medical history of severely impaired hepatic function linked to bicalutamide or a pathological cause. 10. has testosterone level \< 0.5 ng/ml.

Keywords: drug therapy
effect of teriparatide compared to risedronate on back pain in women with a spine fracture caused by osteoporosis

Conditions: Osteoporosis, Postmenopausal; Back Pain; Spinal Fracture

Summary: the purpose of the study is to determine if daily teriparatide reduces back pain more effectively than weekly risedronate in women with osteoporosis who have chronic back pain due to a spinal bone fracture.


Eligibility criteria:
inclusion criteria: * postmenopausal women 45 years or older. no period for at least two years. * history of back pain that started at least 2 months prior to the initial visit (likely due to spinal bone fracture determined by investigator). * minimum of one moderate spinal bone fracture. * beginning pain level of at least four on an eleven point scale. * bone mineral density (bmd) must meet criteria * able to read, understand, and administer self-questionnaires. * be willing and able to use a pen-injector to deliver the medication. exclusion criteria: * are at increased risk for osteosarcoma. * have an active or suspected diseases that affects bone metabolism other than osteoporosis. * participants that already know that they will require procedures to repair their spinal bone fractures. * abnormal values of certain lab tests. * anything that would make it difficult to determine if the back pain was due to the fracture. * poor medical or psychiatric condition. * alcohol or drug abuse within a year of the study start. * certain malignant neoplasms in the 5 years prior to enrollment. * active liver disease or clinical jaundice. * significantly impaired renal function. * history of nephrolithiasis or urolithiasis within 2 years prior to enrollment. * known contraindication or intolerance to risedronate and/or teriparatide therapy. * treatment with oral strontium or certain therapeutic doses of fluoride.
potential role of donor-derived cell-free dna as a biomarker in cardiac allograft vasculopathy

Conditions: Cardiac Allograft Vasculopathy

Summary: cross-sectional study. we will prospectively obtain ddcf-dna levels in all patients who undergo routine coronary angiography \> 1 year after ht. our main goal is to evaluate the performance of donor-derived cell free dna (ddcf-dna) as a biomarker of cav.


Eligibility criteria:
inclusion criteria: * patients over 18 and under 80 years old, ht \> 1 year ago exclusion criteria: * patients under 18 or over 80 years old * multiorgan transplant * history of acute cellular rejection ≥ 1r or antibody mediated rejection in the previous 6 months * concomitant infection by cmv

Keywords: donor-derived cell free dna heart transplant
comparative study of specific ige levels to common foods and aeroallergens measured by euroimmun allergy and immunocap

Conditions: Allergy

Summary: the purpose of this study is to determine the correlation of specific ige levels to common foods and aeroallergens measured by euroimmun allergy and immunocap

children aged 0-15 years old who was diagnosed as asthma and/or allergic rhinitis, atopic dermatitis, food allergy, and underwent to measured specific ige levels to suspicious relevant allergen, were invited to join the study. specific ige levels of each patient was measured by euroimmun allergy and immunocap. the levels of specific ige to dermatophagoides pteronyssinus, dermatophagoides farinae, american cockroach, bermuda, johnson, cat dander, cow's milk, egg white and wheat were determined the correlation between these two methods.

Eligibility criteria:
inclusion criteria: * clinical diagnosed as asthma and/or allergic rhinitis and/or atopic dermatitis and/or food allergy and have to measured specific ige levels to relevant allergens exclusion criteria: * having underlying disease including cardiovascular disease, chronic lung disease and immunodeficiency disease * denied to enrolled to the study

Keywords: immunoglobulin e, food hypersensitivities, child, allergens
injecting plasma-rich platelets & hyaluronic acid for patients with stress urinary incontinence

Conditions: Stress Incontinence, Female

Summary: injection of prp and hyaluronic acid in stress incontinence patients

operative details dissection of the ant vag wall from the urethra and lower part of the bladder identify the bladder neck using foly s catheter injection of 1.5 to 2 ml prp combined with hyaluronic acid suburethra almost at the level of mid urethra (avoiding the bl neck) then closure of the vag wall ( after removal of the excess vag tissue.

Eligibility criteria:
inclusion criteria: * stress incontinence patients exclusion criteria: * prolapse patients